MAP Pharmaceuticals Resubmits New Drug Application to FDA for LEVADEX® Orally Inhaled Migraine Drug

MAP Pharmaceuticals Resubmits New Drug Application to FDA for LEVADEX® Orally
                            Inhaled Migraine Drug

PR Newswire

MOUNTAIN VIEW, Calif., Oct. 16, 2012

MOUNTAIN VIEW, Calif., Oct. 16, 2012 /PRNewswire/ --MAP Pharmaceuticals, Inc.
(Nasdaq: MAPP) today announced that it has resubmitted its New Drug
Application (NDA) to the United States Food and Drug Administration (FDA) for
LEVADEX® orally inhaled migraine drug for the potential acute treatment of
migraine in adults.

"We have worked diligently on our LEVADEX resubmission and, based on our
dialogue with the FDA, we believe that we have addressed the issues outlined
by the FDA in the Complete Response letter we received in March 2012," said
Timothy S. Nelson, president and chief executive officer of MAP
Pharmaceuticals. "We continue to dedicate ourselves to making this potential
new treatment for migraine sufferers available to many of the millions of
patients whose migraines are not well treated with the options available

About MAP Pharmaceuticals

MAP Pharmaceuticals is a biopharmaceutical company focused on developing and
commercializing new therapies to address undermet patient needs in neurology.
The Company is developing LEVADEX®, an orally inhaled investigational drug for
the acute treatment of migraine. The U.S. Food and Drug Administration (FDA)
reviewed the New Drug Application (NDA) for LEVADEX and on March 26, 2012, the
Company received a Complete Response letter with respect to this NDA. MAP
Pharmaceuticals has entered into a collaboration agreement with Allergan, Inc.
to co-promote LEVADEX to neurologists and pain specialists in the U.S. and
Canada. The Company also applies its proprietary drug particle and inhalation
technologies to generate new pipeline opportunities by enhancing the
therapeutic benefits of proven drugs, while minimizing risk by capitalizing on
their known safety, efficacy and commercialization history. Additional
information about MAP Pharmaceuticals can be found at

CONTACT: Christopher Y. Chai, Sr. Vice President and Chief Financial Officer
of MAP Pharmaceuticals, Inc., (650) 386-3107; or media, Lisa Borland, (650)

SOURCE MAP Pharmaceuticals, Inc.

Press spacebar to pause and continue. Press esc to stop.